Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model

被引:50
作者
Langer, T
Eder, M
Hoffmann, RD
Chiba, P
Ecker, GF
机构
[1] Univ Vienna, Dept Pharmaceut Chem, A-1090 Vienna, Austria
[2] Univ Innsbruck, Inst Pharm, A-6020 Innsbruck, Austria
[3] Univ Orsay, Accelrys, Orsay, France
[4] Med Univ Vienna, Dept Med Chem, Vienna, Austria
基金
奥地利科学基金会;
关键词
P-glycoprotein; pharmacophore model; in silico screening; propafenone; multidrug resistance;
D O I
10.1002/ardp.200300817
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Considerable effort has been devoted to the characterization of P-glycoprotein - drug interaction in the past. Systematic quantitative structure-activity relationship (QSAR) studies identified both predictive physicochemical parameters and pharmacophoric substructures within homologous series of compounds. Comparative molecular field analysis (CoMFA) led to distinct 3D-QSAR models for propafenone and phenothiazine analogs. Recently, several pharmacophore models have been generated for diverse sets of ligands. Starting from a training set of 15 propafenone-type MDR-modulators, we established a chemical function-based pharmacophore model. The pharmacophoric features identified by this model were (i) one hydrogen bond acceptor, (ii) one hydrophobic area, (iii) two aromatic hydrophobic areas, and (iv) one positive ionizable group. in silico screening of the Derwent World Drug Index using the model led to identification of 28 compounds. Substances retrieved by database screening are diverse in structure and include dihydropyridines, chloroquine analogs, phenothiazines, and terfenadine. On the basis of its general applicability, the presented 3D-QSAR model allows in silico, screening of virtual compound libraries to identify new potential lead compounds.
引用
收藏
页码:317 / 327
页数:11
相关论文
共 37 条
[1]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[2]   Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis [J].
Bakken, GA ;
Jurs, PC .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) :4534-4541
[3]  
Bates Susan F, 2002, Novartis Found Symp, V243, P83
[4]   Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers [J].
Boer, R ;
Gekeler, V ;
Ulrich, WR ;
Zimmermann, P ;
Ise, W ;
Schodl, A ;
Haas, S .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) :857-861
[5]   Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom [J].
Chiba, P ;
Annibali, D ;
Hitzler, M ;
Richter, E ;
Ecker, G .
FARMACO, 1998, 53 (05) :357-364
[6]   Substituted 4-acylpyrazoles and 4-acylpyrazolones: Synthesis and multidrug resistance-modulating activity [J].
Chiba, P ;
Holzer, W ;
Landau, M ;
Bechmann, G ;
Lorenz, K ;
Plagens, B ;
Hitzler, M ;
Richter, E ;
Ecker, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (21) :4001-4011
[7]   Studies on propafenone-type modulators of multidrug resistance III: Variations on the nitrogen [J].
Chiba, P ;
Hitzler, M ;
Richter, E ;
Huber, M ;
Tmej, C ;
Giovagnoni, E ;
Ecker, G .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1997, 16 (05) :361-366
[8]  
Chiba P, 1996, MOL PHARMACOL, V49, P1122
[9]   SYNTHESIS, PHARMACOLOGICAL ACTIVITY, AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF A SERIES OF PROPAFENONE-RELATED MODULATORS OF MULTIDRUG-RESISTANCE [J].
CHIBA, P ;
BURGHOFER, S ;
RICHTER, E ;
TELL, B ;
MOSER, A ;
ECKER, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (14) :2789-2793
[10]   Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance [J].
Ecker, G ;
Chiba, P ;
Hitzler, M ;
Schmid, D ;
Visser, K ;
Cordes, HP ;
Csollei, J ;
Seydel, JK ;
Schaper, KJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (24) :4767-4774